Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103631
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103631
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103631
Table 2 Comparison of clinical efficacy, n (%)
Group | CR | PR | SD | PD | ORR | DCR |
Control group (n = 50) | 0 (0.00) | 8 (16.00) | 10 (20.00) | 30 (60.00) | 8 (16.00) | 18 (36.00) |
Observation group (n = 50) | 2 (4.00) | 18 (34.00) | 9 (18.00) | 22 (44.00) | 20 (40.00) | 29 (58.00) |
χ2 | - | - | - | - | 7.143 | 4.857 |
P value | - | - | - | - | 0.008 | 0.028 |
- Citation: Liang LW, Luo RH, Huang ZL, Tang LN. Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(4): 103631
- URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103631.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103631